George Vande Woude, Ph.D., former director of the Advanced Bioscience Laboratories–Basic Research Program at what is now NCI at Frederick, passed away in April. He was known for being a prudent leader and an outstanding scientist (he and his laboratory discovered the MET oncogene in 1984), as well as for his vibrant personality and seemingly limitless energy.
The past year for Ligia Pinto, Ph.D., and her staff has been full of pressure and remote meetings at all hours of the day and night. It’s also been one of partnerships and progress. Pinto heads the Vaccine, Immunity, and Cancer Directorate, the group at the Frederick National Laboratory that’s leading the national SARS-CoV-2 Serological Sciences Network (SeroNet). At this time last year, her laboratories, which specialized in human papillomavirus, antibody science, and serology, had just been asked to help the Food and Drug Administration evaluate the quality of the new SARS-CoV-2 antibody tests that were flooding the market.
The CCR community is profoundly saddened by the recent passing of George Vande Woude, Ph.D., longtime National Cancer Institute (NCI) colleague, former director of the Advanced Bioscience Laboratories (ABL)-Basic Research Program and former director of the Division of Basic Sciences at NCI. George made many important contributions to the current understanding of the molecular biology of cancer.
Though it lasted just 15 years, Frederick’s first clinical oncology program answered multiple fundamental questions in the fledgling field of immunotherapy and primed the local medical community to become the oncology research hub it is today. The Biological Response Modifiers Program (BRMP) received formal recognition from the Department of Health and Human Services 40 years ago today, on April 27.
Researchers have found a potential therapeutic target for lung squamous cell carcinoma (LSCC), the second most prevalent type of lung cancer. This may pave the way for a targeted therapy for LSCC, which currently has no approved targeted therapies.